COVID-19 Clinical Research Tracker
Clinical Studies Exploring Use of Cell-Based Therapies for COVID-19
Currently, 114 clinical studies are listed on www.clinicaltrials.gov that explore the use of cell-based therapies for patients with COVID-19.
41 (36%) of the 114 clinical studies are being conducted in the United States, while 73 (64%) are being conducted abroad.
The vast majority of studies (85%) are either Phase 1 (30%), Phase 2 (25%), or Phase 1/2 (30%) clinical trials.
Two of the studies are Phase 2/3 clinical trials and only one is a Phase 3 clinical trial.
There are 5 expanded access studies; the phase is not known or applicable for the remaining 11 studies.
Similarly, 80% of the clinical trials being performed in the U.S. are either Phase 1 (29%), Phase 1/2 (22%), or Phase 2 (29%) studies. There is one Phase 2/3 clinical trial and one Phase 3 trial being conducted in the U.S.
As summarized in the chart at the right, 34% of U.S. clinical trials exploring the use of cell-based therapies for COVID-19 are being conducted by academic and research institutions. The remaining 66% are being conducted by industry–all small biotech companies–in some cases, in collaboration with health systems.
84 of the 114 studies conducted globally involve the use of mesenchymal stromal cells (MSCs). Twenty-eight of the 84 studies involving MSCs are being conducted in the U.S.
Published Review Articles Exploring Use of Cell-Based Therapies for COVID-19
At least 140 articles have been published in peer-reviewed publications that offer insights on the potential or promise of regenerative medicine and cell therapies for patients with COVID-19. Click here for the list of published articles. See below for a summary of the number of articles by cell type.
The vast majority (96%) of published articles describe the role of MSCs in treating patients with COVID-19. The remaining articles explore the potential of T-reg cells (2), iPSCs (2), natural killer (NK) cells (1), and progenitor cells (1).
Published Results from Clinical Studies Exploring Use of RMCTs for COVID-19
Researchers involved in 27 clinical studies involving the use of cell-based therapies for severely ill patients with COVID-19 have published their results, 25 of which were published or are to be published in peer-reviewed journals.
- Across all 25 studies with results published in peer-reviewed journals, mortality rates averaged 8%, which is less than the average mortality rate for severely ill patients with COVID-19, which ranges from 39 to 72%.
- Nine of the 25 published studies were based on expanded access use of cell-based therapies for COVID patients.
- Only 5 of the 25 published findings were based on randomized, controlled trials, and the other 11 did not include randomization.
- Therefore, the conclusions that can be drawn from published findings to date are limited.
Updated as of March 22, 2021